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Abstract ...  words 
 
 Apart from major illnesses and chronic afflictions, the elderly experience lesser ailments, 
such as muscle weakness, cold intolerance, and transient memory lapses.  Physical signs in the 
aged include wrinkled skin & the slow healing of skin abrasions.  These ailments and signs are 
grouped together because they may be due in part to an age-linked waning microcirculation.  A 
reduced capillary density (CD) throughout the body of aged people and animals has been 
reported in over 40 papers.  The reduced CD is due in turn to declining levels of angiogenic 
growth factors (AGFs) throughout the body during old age, as documented in 7 reports in the 
literature.  From this perspective, old age is a deficiency state of AGFs, much like the reduced 
testosterone levels in elderly males.  The above data on reduced CD and AGFs are the basis for 
the ‘angiogenesis hypothesis of aging’, whose corollary suggests pro-angiogenesis therapy for 
symptoms and signs of old age.  Several angiogenic growth factors are now available in 
recombinant forms (e.g., vascular endothelial growth factor, VEGF) and have been used safely in 
animal experiments and in short term clinical trials. 
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PRO-ANGIOGENESIS THERAPY AND AGING 
 
Introduction  
 Elderly persons may experience a range of medical conditions: a fatal disease (cancer, 
stroke, etc.), chronic afflictions (diabetes, arthritis, atrial fibrillation, etc.), and troubling lesser 
ailments.  The last is a collective term for five minor symptoms and signs of old age, which 
include general muscle weakness, cold intolerance, minor memory lapses, skin wrinkles, and the 
slow healing of bruises or abrasions in the skin [1].  The lesser ailments of aging (LAA) are the 
focus of this review and are grouped together here because they may have a common vascular 
cause and be treatable, as next explained. 
 It is well recognized that atherosclerosis in arteries and arterioles leads to major illnesses 
-- stroke, heart disease, and peripheral vascular disease.  Later in life, changes occur at the 
terminal end of the vascular tree, where capillaries develop looping, kinking, and extensive 
tortuosity [2].  Not commonly appreciated is that capillaries also undergo significant regression 
in absolute number.  Over 40 published studies have reported a reduced capillary density (CD) 
throughout the body of aged animals and people.  These findings are discussed below with 
representative data being listed in Table 1. 
 The development and maintenance of capillaries depend on angiogenesis (AG) -- i.e., on 
genetically programmed levels of angiogenic growth factors (AGFs).  During early growth and 
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maturation of the body, the development and function of various organ systems involve rising 
levels of AGFs and an expanding microcirculation.  But during old age, people and animals 
show declining levels of such factors in various organ systems, paralleling the reduced CD.  Data 
from seven such studies are discussed later and presented in Table 2.  Thus old age represents a 
deficiency condition for AG factors, much like hormone levels which are decreased in the 
elderly.   
 The idea that the lesser ailments may be due in part to age-associated diminished 
CD/AGFs is termed ‘the angiogenesis hypothesis of aging’.  Its corollary suggests that treatment 
with exogenous angiogenic factors should restore reduced CD in areas experimentally depleted 
of capillaries and may improve function in areas of naturally impaired microcirculation.  
Recombinant angiogenic factors have been shown to induce new capillary formation in ischemic 
and normoxic tissues within days, as observed in numerous animal studies mentioned later.  Thus 
in theory, pro-angiogenesis therapy may ease the LAA after they have appeared or delay their 
development.  This is in contrast to the pathology in the larger blood vessels, where fatty plaques 
and cholesterol deposits cannot be readily eliminated once acquired but only prevented in the 
decades before old age by avoiding risk factors -- i.e., obesity, diabetes, hypertension, etc. [3].   
    Because of the biographical constraints of this journal, this paper has been limited to 
presenting studies with key data in support of the angiogenesis hypothesis and in advancing its 
therapeutic corollary.  Not covered here are detailed discussions of specific angiogenic growth 
factors, therapeutic regimens with recombinant forms, and other potential treatments involving 
gene transfer or progenitor cells.  These particular matters were treated in prior papers and in 
numerous primary sources cited in them [4,5]. 
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Reduced Capillary Density in Old Age  
 The age-linked reduction of capillaries in the brain and muscle was the main focus of 
several earlier reviews [4,5].  Representative data from both organ systems are presented 
immediately below.  Since the publication of these papers, additional examples of a reduced CD 
elsewhere in the body have been identified in other research reports and are included later and in 
Table 1.   
 Brain.  An age-linked reduction in capillaries was first described in the brains of older 
rats by E. Horne Craigie in the 1920s [6].  For example, he found CD values of 856 and 638 
in the regio insularis of 2-month and 13-month old rats, respectively.  Here CD values are shown 
as ‘data pairs’ (e.g., 856 vs. 638), indicating average values found in adults versus those in the 
aged.  Listed in Table 1 are seven representative data pairs from four reports [6-9], showing 
reduced cerebral CD in old rats, aged people, and subjects with Alzheimer’s disease (AD).    
 Muscle.  The reduction of CD with age has been reported also in skeletal muscles.  For 
example, Rivard examined the CD in muscles of mice and found an average value of 710 mm3 in 
12-week old mice but only 350 mm3 in 2-year old mice [10].  In the middle of Table 1 are listed 
four representative data pairs from the muscles of mice, rabbits, and people [10,11].   
 Other organs.  A similar reduction in the CD with age has been noted in other areas of the 
body -- skin, larynx, colon, kidneys, and lungs.  For example, Helmbold et al. examined human 
skin and reported the average CD of 4.4 n/HPF for those age 39-40 years and only 2.3 n/HPF for 
those over age 70 [12].  In the lower half of Table 1 are listed representative data from eight 
reports on various parts of the body  [12-19].   
 Lungs.  Among the LAA might be included senile exertional dyspnoea.  While exertional 
dyspnea occurs at all ages and is generally due to cardiac insufficiency or obstructive lung 
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disease, during old age an additional cause may be a lowered alveolar gas exchange due to 
reduced alveolar CD.  Butler and Kleinerman measured pulmonary CD and found a smaller 
capillary density to alveolar diameter ratio (CD/AD) in the lungs of older persons [20].  From 
Table 1 of their paper, I calculated that the CD/AD ratio averaged 0.47 for 15 measurements in 
five adults age 17 to 31 and 0.36 for similar set of data from older persons age 49 to 57.  Georges 
et al. observed a decreased pulmonary capillary blood volume in subjects after 50 years of age 
[21].  Thurlbeck and Angus interpreted a reduction in alveolar parenchymal tissue in aged 
persons as reflecting a loss of pulmonary capillaries because of a widespread, age-linked 
reduction in CD [22].   
 Summary.  Little mention has been made in clinical papers that a reduced CD occurs 
during aging throughout the body, but, as noted above, but this change has been reported in the 
research literature for seven different organ systems.  Evidence of this reduction is the 20 
representative data pairs from 14 reports presented here in Table 1.  To date, a total of the 64 
data pairs from 40 reports have been found, as listed above and in three previous papers [1,4,5].  
The widespread reduced microcirculation is associated chronologically with the development of 
the symptoms and signs of old age in both higher animals and people.  It seems logical to 
consider this reduction as one possible cause of the lesser ailments of old age.      
 
Declining Angiogenesis in Old Age  
 The existence of a vasculogenic factor was first postulated in 1948 by Isaac C. 
Michaelson (1903-1983), a British ophthalmologist, who studied capillary growth in the 
developing retina of cats and people [23].  In 1971, Judah Folkman (1933-2008) isolated an 
angiogenic factor (later termed angiogenin) which promoted the growth of solid tumors by 
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developing a new capillary network nourishing them [24].  Transient local angiogenesis also 
occurs during the ovarian cycle and pregnancy and in areas of wound healing and other injuries 
involving ischemia -- e.g., cerebral infarcts.   
 To my knowledge, there has been no report which has measured the general development 
of the microcirculation throughout life relative to levels of angiogenic factors.  But based on 
Craigie’s study of capillary density in rat brains from birth to late maturity [6, its Fig.4], levels of 
these AG factors must follow a chronological course similar to that of CD -- i.e., they rise 
sharply during early life, peak with the full development of the capillary beds in organ systems, 
remain at a plateau level during maturity, and begin to decline in old age.  Like the reduced CD 
during aging discussed in the previous section, waning levels of angiogenic factors in later life 
have been documented by many investigators in numerous organ systems (see below).  As noted 
earlier, this age-linked decline seems analogous to the falling values of testosterone in older men 
and the declining levels of other hormones with age.  An association between the changes in 
hormone level in the aged and the age-linked decline in AGFs was discussed in a prior paper [5]. 
 Angiogenesis involves various vascular growth factors, some working in concert with 
others [25].  Three well-studied such agents are vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF-1 & -2), and angiopoietin (AP-1 & -2).  These and other growth 
factors have been extensively reviewed elsewhere [26].  The aspect of angiogenesis relevant for 
this paper is the finding that these factors in the body decline during old age.   
 Organ systems affected.  While there are no published reports on levels of angiogenic 
factors in the aging human brain, Viboolvorakul & Patumraj found reduced VEGF protein in the 
parietal cortex of aged rats -- e.g., values of 32.3 pg/mg protein in 4-5 month old rats vs. 20.5 
pg/mg protein in 23-24 month old rats [27].  Reduced levels of VEGF protein and/or mRNA 
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VEGF have been recorded in other organ systems of the aged mice, rats, or humans -- i.e., in the 
muscles, kidney medulla, vein wall, mononuclear cells, and macrophages.  In Table 2 are listed 
ten representative data pairs showing diminished levels of angiogenic factors in six organs or cell 
systems of aged people and animals. [19, 27-32].  A general decline in AG throughout the human 
body would account for the reduced CD observed in many organ systems of the elderly.  How 
such a decline may lead to aged-looking skin and long lasting bruises is explained below.   
 Aging Skin.  The skin on the face, upper arms, and dorsum of the hands of elderly 
persons becomes loose and wrinkled due to loss of subcutaneous fat.  Throughout adulthood, 
adipose tissue can expand or regress, as many weight watchers know.  Body fat is highly 
vascularized with an extensive capillary network surrounding each adipocyte.  Rupnick et al. 
reported that angiogenesis inhibitors “significantly decreased” adipose tissue in mice and 
concluded that adipose tissue mass is “regulated by its vasculature” -- i.e., via local angiogenesis 
[33].  Thus the age-linked decline in AG in the elderly people may cause depletion of 
subcutaneous fat notably in the hand dorsum, leading to the loss of a filling/smoothing effect 
there.  Three data pairs showing a reduced CD in aged skin (likely also in its subcutaneous fat) 
are listed in Table 1.  Visceral/abdominal fat is less responsive to angiogenic control, which may 
account for a fat belly in persons with wrinkles elsewhere [34].  
 Slow healing skin lesions.  Bruises and small abrasions on the skin are more conspicuous 
in elderly people than in younger ones, perhaps because these injuries are slower to heal in the 
former.  Various conditions account for this greater incidence, including increased capillary 
fragility with age.  In old mice and rats slow healing has also been ascribed to a “decrease in 
capillary growth” and “delayed angiogenesis” [35,36].    
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Pro-Angiogenesis by Angiogenic Growth Factors  
 Support for the therapeutic corollary of the angiogenesis hypothesis comes from studies 
showing that recombinant angiogenic growth factors improve the local microcirculation or 
function not only in ischemic areas but also in normoxic organs. 
 Animal brain studies.  See Table 3A [37-40].  Using an osmotic minipump, Rosenstein et 
al. infused recombinant VEGF to a 3 mm depth near the coronal/sagittal sutures in normal adult 
rats and observed “remarkable neovascularization” in the involved cortical area [37].  Another 
group injected basic fibroblastic growth factor into the lateral ventricle of normal rats and 
reported increased angiogenesis in the adjacent brain cortex [38].  Thau-Zuckner et al. 
administered VEGF into the later ventricle of mice following traumatized brain injury and noted 
increased angiogenesis in the affected area [39].  Improved motor function and memory followed 
intraventricular doses of VEGF in mice and rats subject to focal cerebral ischemia [40].   
 Animal muscle studies.  An experimental model for inducing angiogenesis in muscles has 
involved occluding the femoral artery of a hind limb of rabbits, rats, or mice to render it 
ischemic.  Different AGFs (VEGF, bFGF) were injected by various routes and produced an 
increased local CD.  Three such reports are listed in Table 3B, where the details of therapy are 
abstracted in the middle column [10,41,42].     
 Clinical muscle trials.  Persons with limited walking tolerance (ca. 5 minutes) due to 
intermittent claudication were given bilateral femoral artery infusions of FGF-2 according to 
various schedules.  In some groups, the Day 90 walking time was increased by 1-2 minutes 
beyond the base line level [43].  The maximum tolerated dose was 30 g/kg; higher level 
induced acute hypotension.  Cautions concerning pro-AG therapy were discussed elsewhere [4]. 
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 Clinical myocardium trials.  Patients with impaired cardiac function have received one or 
several injections into the myocardium of recombinant proteins of various angiogenic growth 
factors [44].  While initial reports suggested favorable results, later evaluations showed 
equivocal long-term clinical benefit in double blind, randomized placebo-control trials [44].  
However, these studies demonstrated the safety of the recombinant factors.  A table in the paper 
by Annex and Simons lists the results in nine clinical trials involving angiogenic protein therapy 
in subjects with myocardial insufficiency [44]. 
 Clinical brain study.   Harry S. Goldsmith performed an extraordinary surgical procedure 
which suggested that raising the cerebral level of AGFs would benefit persons with Alzheimer’s 
disease.  The rationale for his work rested on the extremely high levels of VEGF protein in rat 
omentum -- viz., 884 pg/mg compared to 8 pg/mg (sic) in the brain brain [45].  Goldsmith 
‘stretched’ an omental pedicle flap from the transverse colon of human subjects with AD onto 
the surface of their brains.  This was done by pulling an omentum flap from the colon through a 
subcutaneous pathway up the anterior abdominal wall, chest, and neck to the base of the skull.  
After being brought through openings in the skull, the dura mater, and arachnoid membrane, the 
end of the omentum flap was laid directly on the parietal-temporal area of one hemisphere -- all 
the while maintaining its original circulation [46].  Some AD subjects subsequently exhibited 
marked cognitive improvement [46].  Post mortem examination of a dozen or so AD cases given 
such flap-grafts showed that collateral circulation had been established in the area under the 
pedicle and had also increased the microcirculation in zones apart from the omental placement, 
such as the occipital area and contralateral cerebral hemisphere [46].  These findings indicate 
that local angiogenesis was induced by the growth factors released into the brain from the viable 
flap.  
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Advocates of Pro-Angiogenesis for Maintaining the Microcirculation  
 Pro-angiogenesis treatment of the elderly has inferential support from the comments of 
investigators regarding the importance of angiogenesis in maintaining the microvascular system.  
In 1986, Bär wrote that the capillary plexus “needs a continuous action of an angiogenic 
stimulus” [47: p. 223].  In 1992, Ferrara concluded that the “presence of growth factor[s] may be 
required to maintain the differentiated state of those vessels” [48: p. 28].  In 2005, Carmeliet 
stated, “Threshold levels of VEGF [are needed] for the survival and maintenance of quiescent 
vessels in healthy organs” [49: p. 936]. 
 Baumgartner and Isner prefaced a 1998 article as follows: “Angiogenic growth factors 
constitute a potentially novel form of therapy for patients with ischemic vascular diseases” [50: 
p. 201].  In 2011, Carmeliet & Jain concluded that “The revascularization of ischaemic tissues 
would benefit millions, but therapeutic angiogenesis is an unmet medical need” [26: p. 298].   
 
Clinical assessment    
 Evaluating the clinical benefit of any pro-angiogenesis therapy in the elderly would rest 
mainly on subjective self-appraisals, such as sensing improved strength or noting ‘a sharper 
memory’ -- fewer instances of lapsed recall of names or facts.  Currently, the only objective 
measurement of an increased CD would be histologic studies on muscle biopsies or at autopsy.  
CD visualized under the fingernails, in the forearm skin, or in the conjunctiva have as yet 
insufficient background data on which to evaluate any small improvement during a therapeutic 
trial.  Simons remarked on the absence of any useful biomarkers for CD in subjects in a clinical 
trial and cautioned about a placebo effect [25]. 
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Conclusions    
.   Countless theories have been advanced to explain aging in people, but none has led to a 
widely accepted treatment based on reversing an underlying cause [1,51].  Physiological aging is 
commonly assumed due to various causes.  Indeed, if aging is the result of several enfeebling 
influences, then lessening any one might ease its symptoms and signs.  Again, there is abundant 
evidence in the literature that a reduced CD and a waning AG occur during old age.  It seems 
likely that these linked changes influence the physiological state of the aged body -- accounting 
for its fading functions and possibly for the lesser ailments.  A reduced cerebral CD may 
contribute to the more profound cognitive problems of old age -- e.g., Alzheimer’s disease. 
 Animal studies described above establish that exogenous AGFs generate new capillaries.  
While numerous investigators have administered recombinant angiogenic growth factors to 
relieve specific conditions of ischemia in the human body, to my knowledge no gerontologist has 
proposed pro-angiogenesis therapy for moderating or delaying the wide-spread reduced 
microcirculation occurring during old age.  Therapeutic pro-angiogenesis seems a tenable 
consideration for the lesser ailments of the elderly.  The 30 data pairs in Tables 1 & 2 bring to 
mind George Orwell’s admonition, “To see what is in front of one’s nose needs a constant 
struggle” [52]. 
 
 
 
 
 
1 
 
 
 
Acknowledgements       
 I gratefully acknowledge the invaluable assistance of Mrs. Amanda Williams, Medical 
Center Library, University of Kentucky and the continued support of I.S. Tray II.   
 
References for Text 
  1.  Ambrose CT: The Role of Capillaries in the Lesser Ailments of Old Age and in Alzheimer’s 
Disease and Vascular Dementia: the Potential of Pro-Therapeutic Angiogenesis. J Alzheimer’s 
Dis 2016; 54: 31-43.  
 2.  Kalaria RN, Kroon SN: Expression of leukocyte antigen CD34 by brain capillaries in 
Alzheimer’s disease and neurologically normal subjects.  Acta Neuropathol 1992; 84, 606-612.   
 3.  de la Torre JC: Vascular risk factor detection and control may prevent Alzheimer’s disease. 
Ageing Res Rev 2010; 9: 218-225. 
 4.  Ambrose CT: A Therapeutic Approach for Senile Dementias: Neuroangiogenesis.  J 
Alzheimer’s Dis 2015A; 43: 1-17.  
 5.  Ambrose CT: Muscle weakness during aging: a deficiency state involving declining 
angiogenesis. Ageing Res Rev 2015B; 23: 139-153. 
6.  Craigie EH: Postnatal changes in vascularity in the cerebral cortex of the male albino rat.  J 
Comp Neurol 1925; 39: 301-324.   
 7.  Buchweitz-Milton E, Weiss HR:  Perfused Capillary Morphometry in the Senescent Brain.  
Neurobiol Aging 1987; 8: 271-276.   
2 
 
  8.  Mann DM, Eaves NR, Marcyniuk B, Yates PO: Quantitative changes in cerebral cortical 
microvasculature in ageing and dementia. Neurobiol Aging 1986; 7: 321-330.  
  9.  Fischer VW, Siddiqi A, Yusufaly Y: Altered angioarchitecture in selected areas of brains 
with Alzheimer’s disease. Acta Neuropath 1990; 79: 672-679.     
10.  Rivard A., Fabre J-E., Silver M., Chen D., et al: Age-dependent impairment of angiogenesis.  
Circulation 1999; 99: 111-120.  
11.  Coggan AR, Spina RJ, King DS, Rogers MA, Brown M, Nemeth PM, Holloszy JO: 
Histochemical and enzymatic comparison of the gastrocnemius muscle of young and elderly men 
and women. J Gerontology: Biolog Sci 1992; 47: B71-B76.  
12.  Helmbold P, Lautenschläger C, Marsch WC, Navak RC: Detection of a Physiological 
Juvenile Phase and the Central Role of Pericytes in Human Dermal Microvascular Aging.  J 
Invest Dermatol 2006; 126: 1419-1421.  
13.  Vollmar B, Morgenthaler M, Amon M, Menger MD:  Skin microvascular adaptations during 
maturation and aging of hairless mice. Am J Physiol Heart Circ Physiol 2000; 279: H1591-
H1599.    
14.  Výbohová V, Mellová Y, Adamicová K, Adamcov M, Hešková G: Quantitative changes of 
the capillary bed in aging human skin. Histol Histopathol 2012; 27: 961-967.   
15.  Russell JA, Nagai H, Connor NP: Effect of Aging on Blood Flow in Rat Larynx. The 
Laryngoscope 2008; 1l8: 559-563. 
16.  Gabella G: Development and ageing of intestinal musculature and nerves: the guinea-pig 
taenia coli. J Neurophysiol 2001; 30: 733-766.   
17.  Stefanska A, Eng D, Kaverina N, Duffield JS, Pippin JW, Rabinovitch P, Shankland SJ: 
Interstitial pericyte decrease in aged mouse kidneys. AGING 2015; 7: 370-381.  
3 
 
18.  Urbieta-Caceres VH, Syed FA, Lin J, Zhu X-Y, Jordan KL, Bell CC, Bentley MD, Lerman 
A, Khosla S, Lerman LO: Age-dependent renal cortical microvascular loss in female mice. Am J 
Physiol Endocrinol Metab  2012; 301: E979-E986.  
19.  Kang D-H, Joly AH, OH SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M: Impaired 
Angiogenesis in the Aging Kidney: Vascular Endothelial Growth Factor and Thrombospondin-1 
in Renal Disease. Am J Kidney Dis  2001; 37: 601-611. 
20.  Butler C, Kleinerman J: Capillary density: Alveolar diameter, a morphometric approach to 
ventilation and perfusion. Am Rev Resp Dis 1970; 102: 886-894. 
21.  Georges R, Saumon G, Loiseau A: The relationship of age to pulmonary membrane 
conductance and capillary blood volume. Am Rev Respir Dis 1978; 117: 1069-1078. 
22.  Thurlbeck WM, Angus GE: Growth and aging of the normal human lung. Chest 1975; 67: 
3S-6S.  
23.  Michaelson IC: The mode of development of the vascular system of the retina, with some 
observations on its significance for certain retinal diseases. Trans Ophthalmic Soc UK 1948; 68: 
137-180.  
24.  Folkman J, Klagsbrun M: Angiogenic Factors. Science 1987; 235, 442-447.    
25.  Simons M:  Angiogenesis -- Where Do We Stand now?  Circulation 2005; 111: 1556-1566. 
26.  Carmeliet P, Jain RK: Molecular mechanisms and clinical applications of angiogenesis. 
Nature 2011; 473: 298-307.      
27.  Viboolvorakul S, Patumraj S: Exercise training could improve age-related changes in 
cerebral blood flow and capillary vascularity through the upregulation of VEGF and eNOS.  
Biomed Res Int’l  2014; 2014: 1-12. 
4 
 
28.  Wagatsuma A: Effect of aging on expression of angiogenesis-related factors in mouse 
skeletal muscle. Expl Gerontology 2006; 41: 49-54. 
29.  Ryan NA, Zwetsloot KA, Westerkamp LM, Hickner RC, Pofahl WE, Gavin TP:  Lower 
skeletal muscle capillarization and VEGF expression in aged vs. young men. J Appl Physiol 
2006; 100: 178-185. 
30.  Drubaix I, Giakoumakis A, Robert L, Robert AM:  Preliminary data on the age-dependent 
decrease in basic fibroblast growth factor and platelet-derived growth factor in the human vein 
wall and in their influence on cell proliferation. Gerontology 1998; 44: 9-14.   
31.  Solerta SB, Fioravantil M: Downregulation of vascular endothelial growth factor generation 
from immune cells in Alzheimer’s disease. Neurobiology Aging 2002; 23 (suppl 1): S532. 
32.  Swift ME, Kleinman HK, DiPietro LA: Impaired Wound Repair and Delayed Angiogenesis 
in Aged Mice. Lab Invest 1999; 79: 1479-1999. 
33.  Rupnick MA, Panigrahy D, Zhang C-Y, Dallabrida SM, Lowell BB, Langer R, Folkman MJ:    
Proc Na Acad Sci USA 2002; 99: 10730-10735. 
34.  Gealekman O, Guseva N, Hartigan C, Apotheker S, Gorgoglione M, et al:  Depot-Specific 
Differences and Insufficient Subcutaneous Adipose Tissue Angiogenesis in Human Obesity. 
Circulation 2011; 123: 186-194.   
35.  Swift  ME, Kleinman HK, DiPietro LA: Impaired Wound Repair and Delayed Angiogenesis 
in Aged Mice. Lab Invest 1999; 79: 1479-1499. 
36.  Yamaura H, Matsuzawa T: Decrease in Capillary Growth During Aging Exp Geront 1980; 
15: 145-150. 
5 
 
37.  Rosenstein JM, Mani N, Silverman WF, Krum JM: Patterns of brain angiogenesis after 
vascular endothelial growth factor administration in vitro and in vivo. Proc Nat Acad Sci USA 
1998; 95: 7086-7091. 
38.  Puumala M, Anderson RE, Meyer FB: Intraventricular infusion of HBGF-2 promotes 
cerebral angiogenesis in Wistar rat. Brain Res 1990; 534: 283-286. 
39.  Thau-Zuchman O, Shohami E, Alexandrovich AG, Leker RR: Vascular endothelial growth 
factor increases neurogenesis after traumatic brain injury.  J Cerebral Blood Flow Metab 2010; 
30: 1008-1016. 
40.  Wang Y, Galvan V, Gorostiza O, Ataie M, Jim K, Greenberg DA: Vascular endothelial 
growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral 
ischemia in the rat. Brain Res 2006; 1115: 186-193. 
41.  Baffour R, Berman J, Garb JL, Rhee SW, Kaufman AJ, Friedmann P: Enhanced 
angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast 
growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic 
fibroblast growth factor.  J Vasc Surg 1992; 1: 181-191.   
42.  Yang HT, Deschenes MR, Ogilvie RW, Terjung RL: Basic fibroblast growth factor 
increases collateral blood flow in rats with femoral arterial ligation. Circulation Res 1996; 79: 
62-69. 
43.  Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, 
Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH: Therapeutic angiogenesis 
with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a 
randomized trial. Lancet 2002; 359: 2053-2058. 
6 
 
44.  Annex BH, Simons M:  Growth factor-induced therapeutic angiogenesis in the heart: protein 
therapy.  Cardiovascular Res 2005; 65: 649-655. 
45.  Zhang Q-X, Magovern CJ, Mazck CA, Budenbender KT, Ko W, Rosengart TK: Vascular 
endothelial growth factor in omentum: mechanism of the omentum-mediated angiogenesis. J 
Surg Res 1997; 67: 147-154. 
46.  Goldsmith HS, Bacciu P, Cossu M, Pau A, Rodriguez G, Rosadini G, Ruju P, Viale ES, 
Turtas SW, Viale GL: Regional cerebral blood flow After omental transposition to the ischaemic 
brain in man. A five year follow-up study.  Acta Neurochirugica 1990; 106: 145-152.   
47.  Bär T, Miodonski A, Budi Santoso AW:  Postnatal development of the vascular pattern in 
the rat telencephalicpia-arachnoid. Anat Embryo 1986; 174: 215-223.   
48.  Ferrara N, Houck K, Jakeman L, Leung DW: Molecular and Biological Properties of the 
Vascular Endothelial Growth Factor Family of Proteins. Endocrine Rev 1992; 13: 18-32.   
49.  Carmeliet P: Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.   
50.  Baumgartner I, Isner JM: Stimulation of peripheral angiogenesis by vascular endothelial 
growth factor (VEGF).  VASA 1998; 27: 201-206. 
51.  Weinert BT, Timiras PS: Theories of Aging.  J Appl Physiol 2003; 95: 1706-1716. 
52.  Orwell G: In Front of Your Nose.  London’s Tribune, 22 March 1946.       
  
 
 
 
 
1 
 
 
 
 
 
 
Table 1:  CAPILLARY  DENSITY (CD)                   
           ADULT              AGED  (or AD) 
BRAIN   
--  Craigie 1925  [6] 
     --  rats … regio insularis                                  856  (5 mo.)                        638   (13 mo.) 
--  Buchweitz-Milton 1987  [7]    
    --  rats … cortex           830  (8-10 mo.)                 577  (21-33 mo.) 
    --  rats … 6 brain areas         837     “                               592       “   
--  Mann 1986  [8]                                      
    --  people … frontal cortex         966  (26-58 yr.)                   784  (76-96 yr.) 
--  Fischer 1990 … normal vs. AD subjects  [9]    
    --  pre-frontal cortex         94.6  (23-90 yr.)               75.4  (AD, 76-92 yr.) 
    --  basal forebrain          86.8       “                           42.7  (AD     “          ) 
    --  hippocampus          82.         “                           50.2  (AD     “          )   
MUSCLE  
--  Rivard 1999  [10] 
     --  mice                                 710  (12 wk.)                       350  (2 yr.) 
     --  rabbits                             170  (6-8 mo.)                     130  (4-5 yr.) 
--  Cogan 1992  [11] 
     --  male subjects                            308  (av. 24 yr.)                   228  (av. 64 yr.) 
     --  female   “                         338       “                              248       “ 
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SKIN   
--  Helmbold  2006  [12]  
     --  human chest area                                         4.4  (15-20 & 39-40 yr.)     2.3  (>70 yr.)                                    
--  Vollmer 2000  [13]  
    --  hairless rat ear                                             77.6  (30 wk.)                      37.5  (78 wk.) 
--  Vybohova  2012  [14] 
    --  human chest area, %/unit area                     1.42  (31-50 yr.)               0.47  (81-89 yr.)   
LARYNX  
--  Russell 2008  [15] 
      -- rat thyroarytenoid muscle         17.0  (9 mo.)                       9.35  (28-30 mo.)  
COLON      
--  Gabella 2001  [16] 
     --  guinea pig colon muscle, CD                       9 /unit area  (n.s.)              5 /unit area  (n.s.)    
KIDNEY   
--  Stefanska  2015  [17] 
     --  mouse kidney cortex, CD                             1.40  (3 mo.)                      0.93  (27 mo.) 
     --  mouse kidney medulla, CD                          1.52     “                             1.04      “ 
--  Urbieta-Caceres  2012  [18] 
    --  mouse renal cortex, CD                                  30  (6 mo.)                       17  (18-22 mo.) 
--  Kang  2001  [19]                                                                  
    --  rat kidney, peritubular, CD                            11.3%  (3 mo.)                  5.4%  (24 mo.)                  
      
  NOTE:  n.s. =  precise ages not stated ... The units of measurements for the above data differ among the  
     studies and are omitted to keep these tables less cluttered.    
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Table 2:  LEVELS  of  ANGIOGENIC FACTORS   
                                                                           ADULT        AGED (also AD) 
BRAIN  
--  Viboolvorakul 2014  [27]  
    --  rats … parietal cortex, VEGF                   32.3  (4-6 mo.)                20.5  (23-24 mo.)   
MUSCLE  
--  Wagatsuma 2006  [28] 
     --  mice … VEGF           1.0  (av. 2.5 mo.)        0.7  (22 mo.) 
--  Ryan 2006  [29] 
     --  men … VEGF                     1.05  (19-25 yr.)        0.55  (60-72 yr.) 
     --  men … mRNA VEGF       1.0       “         0.4        “ 
     --  men exercise … mRNA VEGF      3.4       “         1.8        “ 
KIDNEY  
--  Kang  2001  [19]                                                                      
    --  rat, kidney medulla, VEGF                        39.3%  (3 mo.)              19.2%  (24 mo.) 
VEIN WALL  
--  Drubaix 1996  [30] 
     --  human ... bFGF                              180   (20-24 yr.)              50   (61-82 yr.) 
MONONUCLEAR CELLS  
--  Solerte 2002  [31] 
    --  human … VEGF       296  (av. 32.2 yr.)           137  (av. 77 yr.)   
  “       “                   296        “                     125  (AD, av. 76.5 yr.)    
MACROPHAGE, activated by IFN-ɤ 
--  Swift 1999  [32] 
     --  mice ... secreted VEGF, pg/ml                  198.9  (2-3 mo.)              124.0  (22-24 mo.) 
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 Table 3.  TREATMENT WITH AN ANGIOGENIC GROWTH  FACTOR    
 
A.  BRAIN 
--  Rosenstein 1998 [37]  rat VEGF      3 mm depth near           vascular tissue in                                                                                                                                        
          coronal/sagittal sutures                          infusion site  
 
--  Puumala 1990 [38]  rat FGF2/b    left lateral ventricle      CD in left perilateral                     
                                                                                                                                  ventricular cortex    
                                                                                                                               
--  Thau-Zuckner 2010 [39]  mice    VEGF     lateral ventricle       angiogenesis in brain 
                                                                                                                                  area traumatized       
     
            
--  Wang 2006 [40]             rat VEGF     intraventricular doses    motor/memory function 
                                                                                                                   after focal cerebral ischemia 
 
 
  
B.  ISCHEMIC LIMB MODEL       
--  Rivard  1999 [10]             rabbits, mice      VEGF, IV bolus  x1                       CD    
--  Baffour 1992  [41]            rabbits                rh bFGF, IM  qd, x2 wks               CD 
--  Yang 1996 [42]                 rats                     bFGF, subQ pump  x14 days         CD 
 
NOTE:   = increase ...  rh = recombinant  
 
 
 
 
